Manufacture of VAQTA(TM), an inactivated hepatitis A virus vaccine, include
s extensive purification of the intact virus particle to remove endogenous
components from the host cell culture lysate as well as compounds introduce
d in the upstream purification process. Analysis of the final purified hepa
titis A virus product by SDS-PAGE prior to inactivation shows that greater
than 95% of the protein in the preparation is found in four protein bands,
which have been confirmed to be hepatitis A virus capsid proteins VP0. VP1,
VP2 and VP3 based on Western blot and mass spectrometry analyses. Validati
on of the manufacturing process and direct analysis of the final product we
re used to demonstrate that no other specific host cell-derived components
are detected and that process residuals are all below the limits of detecti
on of the assays used. Establishment of a rigorous standard of high purity
for this product was pursued to minimize the impact of impurities during cl
inical development of this product and will facilitate the incorporation of
this product into combination vaccines. (C) 1999 Elsevier Science Ltd. All
rights reserved.